Related Experiment Videos
HIV-1 Tat-based vaccines: from basic science to clinical trials
Emanuele Fanales-Belasio1, Aurelio Cafaro, Andrea Cara
1Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
DNA and Cell Biology
|October 25, 2002
Summary
Human immunodeficiency virus (HIV)-1 Tat protein is a conserved target for vaccines. Tat-based vaccines in monkeys controlled infection, leading to human clinical trials for HIV prevention and therapy.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Human immunodeficiency virus (HIV)-1 vaccine development requires antigens conserved across clades.
- The HIV-1 Tat protein is highly conserved and essential for viral replication, making it a promising vaccine target.
Purpose of the Study:
- To evaluate the immunogenicity and efficacy of HIV-1 Tat protein as a vaccine candidate.
- To assess the effect of Tat protein on dendritic cells and its role in immune responses.
Main Methods:
- Studies included in vitro analysis of Tat protein interaction with monocyte-derived dendritic cells (MDDCs).
- Vaccination trials were conducted in monkeys using Tat protein or DNA vaccines.
Main Results:
- HIV-1 Tat protein is efficiently taken up by MDDCs, promoting T helper (Th)-1 immune responses.
- Tat-based vaccination in monkeys controlled early-stage SHIV89.6P infection, limiting viral spread.
Conclusions:
- The HIV-1 Tat protein is a viable candidate for developing effective HIV vaccines.
- Tat-based vaccines show potential for both preventive and therapeutic applications, with Phase I clinical trials commencing.